An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Effect of Oral Doses of SCY-078 (Ibrexafungerp) on the Pharmacokinetics of Dabigatran Administered Orally to Healthy Subjects
Latest Information Update: 22 Apr 2021
At a glance
- Drugs Ibrexafungerp (Primary) ; Dabigatran etexilate
- Indications Candidiasis; Invasive bronchopulmonary aspergillosis; Pneumocystis pneumonia; Vulvovaginal candidiasis
- Focus Pharmacokinetics
- Sponsors SCYNEXIS
Most Recent Events
- 17 Mar 2021 Results presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 04 Aug 2020 Status changed from recruiting to completed.
- 09 Oct 2019 Status changed from not yet recruiting to recruiting.